Literature DB >> 15073602

Validation of tissue microarray technology in ovarian carcinoma.

Daniel G Rosen1, Xuelin Huang, Michael T Deavers, Anais Malpica, Elvio G Silva, Jinsong Liu.   

Abstract

High-throughput tissue microarray allows many clinical specimens to be analyzed simultaneously on a single slide. One potential limitation of tissue microarray is the correct representation of each tumor with the small tissue core. Because tumors from different organs have different levels of heterogeneity, it requires a validation study for each one of them. We compared immunostaining of Ki-67, estrogen receptors, and p53 in whole sections of 45 cases of high-grade serous ovarian carcinoma with six core samples from those sections with regard to the number of tissue cores needed to reliably represent a whole section. Staining for Ki-67 was graded high or low by automated image analysis of 10 high-power fields; staining for estrogen receptor and p53 was scored on a 0-to-3 scale. Correlation coefficients for whole-section vs core stains were 0.86 for Ki-67, 0.93 for estrogen receptors, and 0.82 for p53. A total of 54 (6.6%) of the cores were inadequate for scoring. The probability that results from one core would correctly represent all three markers in the whole section was 91%; that for two cores was 96%; and that for three cores was 98%. Our results show that analysis of a single readable core matched the staining pattern of a whole section more than 90% of the time, and analysis of two cores increased that value to more than 95%, demonstrating that ovarian carcinoma tissue microarray is a reliable technique to analyze the expression of markers. Copyright 2004 USCAP, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073602     DOI: 10.1038/modpathol.3800120

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

1.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

2.  The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.

Authors:  Livia Quattrocchi; Andrew R Green; Stewart Martin; Lindy Durrant; Suha Deen
Journal:  Virchows Arch       Date:  2011-04-21       Impact factor: 4.064

3.  Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Margaret A Gates; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

4.  An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Authors:  Alison Y Zhang; Karen Chiam; Ygal Haupt; Stephen Fox; Simone Birch; Wayne Tilley; Lisa M Butler; Karen Knudsen; Clay Comstock; Krishan Rasiah; Judith Grogan; Kate L Mahon; Tina Bianco-Miotto; Carmela Ricciardelli; Maret Böhm; Susan Henshall; Warick Delprado; Phillip Stricker; Lisa G Horvath; James G Kench
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

5.  Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas.

Authors:  Hee Jin Chang; Byong Chul Yoo; Sun Whe Kim; Byung Lan Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

6.  Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform.

Authors:  Minseok S Kim; Taemin Kim; Sun-Young Kong; Soim Kwon; Chae Yun Bae; Jaekyu Choi; Chul Hwan Kim; Eun Sook Lee; Je-Kyun Park
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

7.  Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.

Authors:  Yoon-La Choi; Ensel Oh; Sarah Park; Yeonju Kim; Yeon-Hee Park; Kyoung Song; Eun Yoon Cho; Yun-Chul Hong; Jong Sun Choi; Jeong Eon Lee; Jung Han Kim; Seok Jin Nam; Young-Hyuck Im; Jung-Hyun Yang; Young Kee Shin
Journal:  BMC Cancer       Date:  2010-09-23       Impact factor: 4.430

8.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

9.  Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific.

Authors:  Qihui Jim Zhai; Daniel Gustavo Rosen; Karen Lu; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-31

10.  B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.

Authors:  Li Liang; Yi Jiang; Jun-Song Chen; Na Niu; Jin Piao; Jing Ning; Youli Zu; Jing Zhang; Jinsong Liu
Journal:  Hum Pathol       Date:  2016-06-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.